Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)
NCT ID: NCT03288155
Last Updated: 2019-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2017-07-01
2019-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease
NCT02275884
Dopamine Dorsolateral Prefrontal Cortex Behavioural Flexibility
NCT03068884
Remotely-supervised Transcranial Direct Current Stimulation (tDCS) for At-home Treatment of Fatigue and Cognitive Slowing in Parkinson's Disease
NCT03189472
Central and Peripheral Fatigue in Individuals With Parkinson's Disease - Evaluation and Training
NCT01971528
Caffeine as a Therapy for Parkinson's Disease
NCT01738178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this project is to undertake a feasibility preliminary study to determine whether flavonoid-rich cocoa has the potential to improve fatigue in pwPD in order to inform a follow on trial. Participants will be recruited from the European Parkinson Therapy Centre (EPTC) and will be those about to enrol onto the 6 day program. They will be required to consume a cocoa drink each morning for 6 days. They will have measures taken including fatigue measures using visual rating scales, walking tests and several questionnaires will be administered during this time.
Aims:
The hypothesis is that the consumption of a flavonoid-rich pure cocoa beverage will reduce fatigue in pwPD. The aim of this study is to determine the feasibility of a trial to evaluate this proposal.
Design:
This is a randomised double-blind placebo controlled feasibility study in which 20 (+ potentially 20 more if adherence is acceptable and recruitment is progressing as expected) pwPD will be recruited from the European Parkinson Therapy Centre (EPTC), Italy.
Intervention:
A 6 day nutrition intervention period, with a total of 2 assessments (baseline and day 6) where outcome measures will be assessed.
Population:
20 men and women with a diagnosis of PD and who are over 18 years of age. There will be 10 participants in each trial arm.
Outcome Measures:
In order to assess benefits, a range of outcomes will be obtained. Outcome measures include:
Levels of physical activity: wearable activity monitors (worn like a watch)
Dietary patterns: 2-24 hour dietary record
Fatigue levels: Fatigue Severity Scale (FSS) and during the intervention the numerical rating scale (NRS) 3 times daily
Fatigability: performance on 6 minute walk test (physical) and AMIPB cognitive test
Health descriptives: basic health questionnaire, Euroqol (EQ5DVAS), SF36 Health survey, Unified Parkinson's Disease Rating Scale non motor symptoms (UPDRSNMS), routinely administered to the centre by Trescore Hospital.
Duration and follow-up:
Participants will be consented by a trained researcher at the Centre and, if successfully pass the eligibility check will be enrolled into the study. Staff at the Centre will be trained on taking consent by researchers at OBU. Once a participant is enrolled, a baseline assessment (Assessment 1) will be conducted at day 1. Immediately following completion of Assessment 1, participants will be randomly allocated to either the high flavonoid intervention group or the control group, and intervention delivery will begin immediately after allocation. They will be reassessed at day 6. Those in the control group will follow the same procedure, the only difference being that they receive the low flavonoid drink. Alex Reed and the EPTC will inform participant GPs about their involvement in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flavonoid rich cocoa
Dark cocoa beverage rich in flavonoids
Cocoa
Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
Low flavonoid cocoa
A control cocoa beverage low inn flavonoids
Cocoa
Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocoa
Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sufficient mental capacity to consent
* Score of 1-2 on Hoehn and Yahr scale
Exclusion Criteria
* Known psychiatric disorder (clinically diagnosed)
* Contraindications tolerating the cocoa drink
* Other conditions that may be associated with fatigue, e.g. Anaemia
* Condition affecting the central nervous system other than Parkinson's disease (however migraine is allowed)
* Pregnant or lactating
* Objection to contacting their GP and neurologist
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Parkinson Therapy Centre
UNKNOWN
Oxford Brookes University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shelly Coe
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shelly A Coe, PhD
Role: PRINCIPAL_INVESTIGATOR
Oxford Brookes Univeristy
Alex Reed
Role: STUDY_DIRECTOR
European Parkinson Therapy Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
European Parkinson Therapy Centre
Boario, Terme, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Coe S, Andreoli D, George M, Collett J, Reed A, Cossington J, Izadi H, Dixon A, Mansoubi M, Dawes H. A feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue and fatigability in people with Parkinson's (pwP). Clin Nutr ESPEN. 2022 Apr;48:68-73. doi: 10.1016/j.clnesp.2022.01.023. Epub 2022 Jan 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OxfordBU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.